(Q34423658)

2 August 2017

1 reference

title

Emerging drugs in Tourette syndrome (English)

1 reference

2 August 2017

1 reference

2

Joseph Jankovic

1 reference

2 August 2017

Yavuz S Silay

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

Expert Opinion on Emerging Drugs

2 August 2017

published in

1 reference

2 August 2017

volume

10

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

365-380

1 reference

Behavioral interventions for tic disorders

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Objective assessments of longitudinal outcome in Gilles de la Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Long-term follow-up of an epidemiologically defined cohort of patients with Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Neurobiology of Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Tic disorders: new developments in Tourette syndrome and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Aripiprazole: profile on efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Pharmacological options for the treatment of Tourette's disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Problems in the management of attention-deficit-hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Methylphenidate to treat ADHD is not contraindicated in children with tics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Clonidine treatment of Gilles de la Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Deprenyl in attention deficit associated with Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Surgery in Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Treatment of Tourette's syndrome with haloperidol, review of 34 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Drug treatment of adolescent tiqueurs. A double-blind trial of Diazepam and Haloperidol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Clinical features and long-term treatment with pimozide in 65 patients with Gilles de la Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Tourette syndrome, associated conditions and the complexities of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Treatment approaches in Gilles de la Tourette syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Long-term effects of tetrabenazine in hyperkinetic movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Serotonin-dopamine antagonist and Gilles de la Tourette's syndrome: an open pilot dose-titration study with risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

A placebo-controlled trial of risperidone in Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Use of the "inverse neuroleptic" metoclopramide in Tourette syndrome: an open case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Metoclopramide-induced tardive dyskinesia in an infant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Successful treatment of Tourette's disorder with amisulpride

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Prediction of clinical response to methylphenidate in children with attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

A case of Gilles de la Tourette's syndrome with some observations on aetiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Naltrexone suppresses abnormal sexual behavior in Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Ziprasidone: a new atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Tourette syndrome: efficient treatment with ziprasidone and normalization of body weight in a patient with excessive weight gain under tiapride

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Quetiapine for Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Quetiapine in treatment-resistant obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Quetiapine treatment of children and adolescents with Tourette's disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Treatment of tics in tourette syndrome with aripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Nicotine attenuates DOI-induced head-twitch response in mice: implications for Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Effects of donepezil on DOI-induced head twitch response in mice: implications for Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Clinical and attentional effects of acute nicotine treatment in Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Botulinum toxin in the treatment of dystonic tics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Premonitory sensory phenomenon in Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Botulinum toxin in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Neuropsychiatric effects of guanfacine in children with mild tourette syndrome: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Tic reduction with pergolide in a randomized controlled trial in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Examination of the SGCE gene in Tourette syndrome patients with obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Microarray analysis in Tourette syndrome postmortem putamen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

A controlled trial of propoxyphene and naltrexone in patients with tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Naltrexone decreases self-injurious behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

Tardive dyskinesia: are first signs reversible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.365

10.1517/14728214.10.2.365

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference